- Home
- PHAT vs TRVI Comparison
PHAT vs TRVI Comparison
Compare PHAT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- TRVI
- Stock Information
- Founded
- PHAT 2018
- TRVI 2011
- Country
- PHAT United States
- TRVI United States
- Employees
- PHAT N/A
- TRVI N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- TRVI Health Care
- Exchange
- PHAT Nasdaq
- TRVI Nasdaq
- Market Cap
- PHAT 716.5M
- TRVI 725.7M
- IPO Year
- PHAT 2019
- TRVI 2019
- Fundamental
- Price
- PHAT $11.91
- TRVI $7.55
- Analyst Decision
- PHAT Strong Buy
- TRVI Strong Buy
- Analyst Count
- PHAT 5
- TRVI 10
- Target Price
- PHAT $16.40
- TRVI $19.35
- AVG Volume (30 Days)
- PHAT 1.1M
- TRVI 1.4M
- Earning Date
- PHAT 08-07-2025
- TRVI 08-07-2025
- Dividend Yield
- PHAT N/A
- TRVI N/A
- EPS Growth
- PHAT N/A
- TRVI N/A
- EPS
- PHAT N/A
- TRVI N/A
- Revenue
- PHAT $114,039,000.00
- TRVI N/A
- Revenue This Year
- PHAT $194.40
- TRVI N/A
- Revenue Next Year
- PHAT $103.23
- TRVI N/A
- P/E Ratio
- PHAT N/A
- TRVI N/A
- Revenue Growth
- PHAT 1049.82
- TRVI N/A
- 52 Week Low
- PHAT $2.21
- TRVI $2.36
- 52 Week High
- PHAT $19.71
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- PHAT 75.25
- TRVI 59.25
- Support Level
- PHAT $9.82
- TRVI $7.24
- Resistance Level
- PHAT $11.19
- TRVI $7.60
- Average True Range (ATR)
- PHAT 0.71
- TRVI 0.34
- MACD
- PHAT 0.17
- TRVI -0.04
- Stochastic Oscillator
- PHAT 94.07
- TRVI 81.30
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.